

Vaxon-Biotech Presents Preliminary Results from Vx-001 Vaccine Clinical Trial on Lung Cancer

P
R
E
S
S

R
E
L
E
A
S
E

Evry-Genopole, France, June 3rd, 2007 – Vaxon-Biotech announces that the latest clinical data from the Vx-001 cancer vaccine trial on non-small cell lung cancer is presented at the lung cancer general poster session held at the ASCO 43rd Annual Meeting. The data are presented by Dr Kostas Kosmatopoulos, Chief Scientific Officer of Vaxon-Biotech. The meeting is taking place in Chicago, June 1-5, 2007.

About Vaxon-Biotech

Vaxon Biotech, founded in early 2004 and based in Evry Genopole - France, is a product-driven biopharmaceutical company focusing on the discovery and development of innovative vaccines for the treatment of cancer. The first two products under development, Vx-001 and Vx-006, are novel treatments for solid tumors. For more information, go to www.vaxon-biotech.com.

Contacts

Philippe Berthon, PhD
CEO
+33(0)160789210
pberthon@vaxon-biotech.com